PEN
Penumbra Inc
Next earnings Jul 27, 2026 (after close) · consensus $1.20 EPS, $393M rev
Last earnings +0.1% on 2026-05-06
$317.40▲ +23.56%
over 1Y
L $225.54EODHDH $359.40
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+0.1%
1M-3.3%
3M-5.7%
YTD+2.6%
1Y+23.6%
Hold
Conviction
Horizon
Long (>12mo)
Street · 21 analysts
Hold
High-growth medical-device maker hitting a profitability inflection with 67% gross margins, but a 70x P/E prices the good news in.
Penumbra is a fast-growing maker of surgical and medical instruments (notably thrombectomy and vascular devices) that just crossed a major profitability inflection. FY2025 revenue grew 17.5% to $1.40B, but the operating leverage is the story: gross margin reached 67.1%, operating income surged to $189M (from a near-breakeven prior year) and net income jumped to $178M with diluted EPS of $4.52. Operating cash flow rose 41.7% to $239M, and the balance sheet is pristine — liabilities/equity of just 0.28x, equity up 24.0% to $1.43B and effectively no debt burden.
Sources: SEC EDGAR (CIK 0001321732, latest 10-Q filed 2026-05-06) · analysis by claude-code · as of 6/21/2026, 8:46:03 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.